PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS

Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune r...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Iñigo-Marco, Ignacio, Díez-Valle, Ricardo, Garcia-Moure, Marc, Patiño-García, Ana, González Huarriz, Marisol, Jones, Chris, Gomez-Manzano, Candelaria, Fueyo, Juan, Alonso, Marta M, Tejada, Sonia
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2019
Предметы:
Late Breaking Abstracts
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6873625/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz219.1197
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы